captopril has been researched along with Carcinogenesis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arora, G; Bandiera, S; Barrett, SC; Baumert, TF; Chung, RT; Crouchet, E; Del Zompo, F; Durand, SC; El Saghire, H; Felli, E; Fuchs, BC; Fujiwara, N; Ghoshal, S; Giannone, F; Hoshida, Y; Li, S; Lupberger, J; Oudot, MA; Pessaux, P; Pochet, N; Ponsolles, C; Qian, T; Rasha, FA; Schaeffer, E; Schuster, C; Slovic, N; Sojoodi, M; Tanabe, KK; Van Renne, N; Zhu, S | 1 |
1 other study(ies) available for captopril and Carcinogenesis
| Article | Year |
|---|---|
Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Carcinogenesis; Carcinoma, Hepatocellular; Chemoprevention; Disease Progression; ErbB Receptors; Liver Cirrhosis; Liver Neoplasms; Peptidyl-Dipeptidase A; Rats; Transcriptional Activation | 2022 |